Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 11, 2025.

via HealthDay

FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those without health insurance, according to a study published online July 7 in JAMA Network Open.

Jingxuan Zhao, Ph.D., M.P.H., from the American Cancer Society in Atlanta, and colleagues conducted a cross-sectional study involving adults who received a new diagnosis of stage IV melanoma (12,048), non-small cell lung cancer (NSCLC; 152,610), or renal cell carcinoma (18,782) who were identified before and after U.S. Food and Drug Administration approval of ICIs. A six-group propensity score-weighting difference-in-differences (DID) approach was applied to examine changes in survival before and after ICI approval among individuals without insurance or with Medicaid versus those with private insurance for each type of cancer.

The researchers found that for those with a diagnosis of melanoma, two-year overall survival rates increased post-ICI approval among uninsured individuals (16.2 to 28.3 percent) and those with private insurance (28.7 to 46.0 percent), resulting in a widening disparity of 6.1 percentage points after adjustment for sociodemographic characteristics. The survival disparity between people without insurance and those with private insurance widened to 1.3 percentage points among people with a diagnosis of NSCLC. No significant changes were seen in survival differences between people with Medicaid and those with private insurance with the introduction of ICIs.

"Expanding Medicaid to individuals without health insurance coverage may improve their access to effective cancer treatments that are also costly, such as ICIs," Zhao said in a statement.

One author disclosed ties to Pfizer and PRIME Education.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords